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Melanoma: A Novel Co-Inhibitory
Pathway with Potential for
Clinical Intervention
Karsten Mahnke1 and Alexander H. Enk1Inozume et al. describe a novel immunosuppressive mechanism in melanoma
that is triggered by the interaction between CD155 (expressed by melanomas)
and T-cell Ig and ITIM domain (TIGIT) (expressed by tumor inﬁltrating lym-
phocytes). This pathway exists in addition to the “classical” co-inhibitory PD-1-
PD-L1 pathway. Hence, the combinatorial blockage of both pathways by speciﬁc
antibodies resulted in the greatly enhanced effector function of melanoma-
speciﬁc cytotoxic T cells. Given that CD155-TIGIT signaling exerts potent
inhibitory action in different subsets of immune cells and that CD155 is
expressed broadly in several tumor entities, this report points toward a novel
and promising therapeutic strategy to combine different checkpoint blocking
agents for greater success in antitumor therapy.
Journal of Investigative Dermatology (2016) 136, 9e11. doi:10.1016/j.jid.2015.10.048The inhibitory TIGIT-CD155
pathway
Immune responses are regulated by the
concerted action of immunostimulatory
and immunosuppressive signals that are
conveyed between antigen-presenting
cells and effector T cells. The balance
of this interplay is often tipped by
tumors toward a more immunosup-
pressive environment. Thereby, tumorsmay utilize receptors or ligands that
normally would trigger inhibitory
pathways in effector T cells. Several
receptors and/or ligands, such as PD-
L1, PD-1, CTLA-4, CD155, and TIGIT,
have been identified as important reg-
ulatory molecules. Among these the
most recently identified inhibitory pair
is T-cell Ig and ITIM domain (TIGIT) and
its ligand CD155 (Yu et al., 2009).ity Heidelberg, Heidelberg, Germany
Dermatology, Ruprecht-Karls-University
idelberg, Germany. E-mail: karsten.mahnke@The molecule TIGIT was identified
initially in a genome-wide screen for
molecules that (a) are expressed by im-
mune cells and (b) contain the well-
defined inhibitory ITIM motif, which is
known to mediate inactivating signals in
a variety of immune cells. TIGIT is
expressed normally by activated T cells,
regulatory T cells (Treg), and natural
killer (NK) cells. The poliovirus receptor
(CD155) and Nectin-2 (CD112) have
been identified as relevant ligands (Li
et al., 2014; Stanietsky et al., 2009; Yu
et al., 2009). TIGIT competes with the
molecules CD226 and CD96 for bind-
ing to CD155 and CD112, respectively,
but among all respective receptor-ligand
combinations, TIGIT exhibits the stron-
gest affinity for CD155. Interestingly, the
other known receptor for CD155,
CD226, conveys activating signals into
T cells, whereas TIGIT clearly has sup-
pressive activity. This competition of an
inhibitory receptor (TIGIT) and a stim-
ulatory receptor (CD226) for one ligand
(CD155) is reminiscent of the CTLA4-
CD28-B7 axis. This similarity of the
CD155-TIGIT interaction to the already
known suppressive CTLA4-CD28
pathway, as well as the expression of
TIGIT by exhausted T cells and by Treg,
prompted investigators to speculate that
the TIGIT-CD155 axis in tumors might
serve as a checkpoint for tumor growth
(Chauvin et al., 2015; Johnston et al.,
2015; Li et al., 2014).
Inozume et al. (2016) report that
melanoma cell lines, as well as mela-
noma tissue samples, express CD155
strongly. In functional assays, the au-
thors show that the effector functions
are suppressed completely in tumor-
specific T cells that express the corre-
sponding inhibitory receptor TIGIT.
But antibody-mediated blockade of
CD155 could, at least partially, reverse
these effects, leading to increased
antitumor activity by cytotoxic T cells
against the melanoma cells. Interest-
ingly, simultaneous blockade of the
previously identified checkpoint mole-
cule PD-L1 had an additive effect, with
anti-PD-L1 and anti-CD155 antibodies
together restoring the effector func-
tion of tumor infiltrating lymphocytes
almost completely. Thus, in addition
to the already defined PD-L1-PD-1 axis
in melanomas, a second inhibitory
pathway, characterized by CD155-
TIGIT interplay, is active.www.jidonline.org 9
Clinical Implications
 Melanomas express high levels of CD155, a ligand of the inhibitory molecule
T-cell Ig and ITIM domain (TIGIT).
 Engagement of TIGITþ cytotoxic T cells by CD155 suppresses effector
functions.
 Blocking the CD155-TIGIT signaling by antibodies, in combination with anti-
PD-1 blockade, enhances the effector function of cytotoxic T cells.
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10The high expression of CD155 by
melanomas, as described by Inozume
et al. (2016), functions as the inhibi-
tory mechanism only when tumor-
residing T cells express the respective
inhibitory counter receptor TIGIT, thus
making them susceptible to the inhibi-
tory signal. Indeed, in addition to mel-
anoma, TIGIT expression has been
shown to be upregulated in tumor
infiltrating CD8þ T cells in a variety of
solid cancers. Among these are none
small-cell lung carcinomas and colo-
rectal carcinomas (Chauvin et al.,
2015; Johnston et al., 2015). The most
robust TIGIT expression could be
observed in CD8þ T cells, but even
CD4þ T cells from patients with cancer
showed elevated levels of expression.Figure 1. Direct and indirect mechanisms of TIGIT-C
report that melanomas express high levels of CD155.
recruitment of SHP1 to the ITT domain and abrogatio
dimerization is blocked. Thus, CTL effector functions
enriched in tumor tissues and engagement of TIGIT le
function of Treg. CTL, cytotoxic T cells; ITT, immuno
protein kinase; TIGIT, T-cell Ig and ITIM domain.
Journal of Investigative Dermatology (2016), VolumThis establishes a broad T-cell inhibi-
tory function for TIGIT engagement in
tumors. Further analysis has revealed
that TIGITþ T cells frequently co-
express PD-1, assigning them to an
exhausted phenotype of cell that shows
reduced IFN-g secretion and lytic ac-
tivity against melanoma cells.
Mechanisms of TIGIT-mediated
suppression
Mechanisms for how engagement of
TIGIT leads to inhibition of antieT-cell
responses are still uncertain. Explana-
tions range from bystander suppression
(i.e., the induction of Treg and/or sup-
pressive dendritic cells) to T-cell
intrinsic mechanisms (Joller et al.,
2011; Kurtulus et al., 2015; Li et al.,D155einduced suppression. Inozume et al. (2016)
The engagement of TIGIT on CTLs leads to the
n of MAPK signaling. Also activation via CD226
are downregulated. In addition, TIGITþ Treg are
ads to gene expression and enhanced suppressive
receptor tail tyrosine; MAPK, mitogen-activated
e 1362014; Liu et al., 2013; Pauken and
Wherry, 2014; Stanietsky et al., 2009,
2013; Yu et al., 2009). Early experi-
ments have suggested a role for TIGIT in
the induction of regulatory T cells and/
or immunosuppressive dendritic cells
(Joller et al., 2014; Kurtulus et al., 2015;
Yu et al., 2009), but after utilizing
TIGIT/ mice and agonistic anti-TIGIT
antibodies, a T-celleintrinsic role for
TIGIT became evident. When anti-
TIGIT antibodies were applied in T-
cell cultures, the downregulation of the
T-cell receptor a-chain as well as that of
molecules that comprise the TCR
complex were observed. Although
TIGIT contains an ITIM motive, it is not
activated by the engagement of the
ligand CD155, and classical T-cell
inhibitory pathways, as defined in the
PD-1-mediated suppression of T cells,
are also not induced (Joller et al., 2011;
Li et al., 2014; Liu et al., 2013). These
findings led to the further study of the
balance of inhibitory and stimulatory
signals provided by CD155 to either
TIGIT (inhibitory) or CD226 (stimula-
tory) (Pauken and Wherry, 2014).
CD226 is expressed frequently by T
cells, and it has been shown to provide
stimulatory signals, which is in contrast
to inhibitory effects transmitted by TIGIT
engagement. In a series of elegant ex-
periments in CD8þ T cells, it has been
shown that TIGIT interacts directly with
CD226 in the cellmembrane,whereby it
blocks homodimerization of CD226.
Normally homodimerization of CD226
is necessary to induce stimulatory sig-
nals, which then keep T cells “unex-
hausted” and maintain their lytic
function (Johnston et al., 2014). There-
fore, TIGIT is able to abrogate “positive”
CD226 signaling, driving the T cells into
exhaustion (Figure 1).
In addition to the classical ITIM
motif, TIGIT also comprises an immu-
noreceptor tail tyrosine motive that, at
least in NK cells, is also important
for “negative signaling.” In NK cells,
immunoreceptor tail tyrosine (and
not ITIM) recruits SHIP1 via ß-arrestin,
leading to termination of phosphati-
dylinositol 3-kinase and mitogen-
activated protein kinase signaling.
Consequently, killing activity and IFN-g
secretion are substantially abolished in
NK cells after the TIGIT-CD155 inter-
action (Li et al., 2014; Liu et al., 2013;
Stanietsky et al., 2009, 2013).
COMMENTARYGiven that TIGIT has profound
inhibitory actions in T cells, the report
by Inozume et al. (2016) establishes the
importance of CD155 expression by
melanomas for the regulation of anti-
tumor immune responses. They show
unidirectional signaling from CD155þ
melanoma cells to effector T cells,
resulting in abrogation of the effector
function. The significance of this finding
for human melanoma is even broad-
ened by recent results, showing that not
only melanomas express the TIGIT-
ligand CD155, but antigen-presenting
cells are also highly positive for
CD155 in patients with melanoma
(Chauvin et al., 2015). Furthermore,
the competing stimulatory receptor
for CD155, CD226, is rather down-
regulated in tumor infiltrating lympho-
cytes. Therefore, a comprehensive
cellular expression of CD155, together
with reduced expression of the
counteracting costimulatory molecule
CD226 by tumor infiltrating lympho-
cytes, may contribute to the extended
immune suppression observed in pa-
tients with melanoma.
Inhibition of TIGIT engagement
by blocking CD155 or TIGIT itself,
as proposed by Inozume et al.
(2016), may even have additional
immune-activating properties beyond
the mere abrogation of the suppressive
TIGIT signaling in T cells. TIGIT-
CD155 interactions have also pro-
found effects on inducing suppressive
bystander cells (Figure 1). For instance,
TIGIT-CD155 signaling leads to the
induction of IL-10þ immature, and
thus suppressive, dendritic cells and to
Treg (Kurtulus et al., 2015; Yu et al.,
2009). Treg play an important role
in creating an immunosuppressiveenvironment in many tumors. This
corresponds to the fact that elevated
suppressive functions and TIGIT sig-
naling in Treg induce gene expression
that stabilizes their phenotype (Bin
Dhuban et al., 2015; Kurtulus et al.,
2015; Lozano et al., 2012).
In summary, the report by Inozume
et al. (2016) shows the importance of
a second, PD-1-independent immune
checkpoint pathway that is present in
several tumor entities. The simulta-
neous blockade of the previously
identified PD-1 pathway and the
CD155-TIGIT pathway completely re-
constitutes the effector function of
cytotoxic T cells in an in vitro system.
Combination therapies that include
antibodies that block CD155-TIGIT
signaling offer a promising strategy to
improve anticancer therapy.
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